Anthropic Long-Term Benefit Trust Appoints Vas Narasimhan to Board of Directors

Anthropic's Long-Term Benefit Trust has appointed Vas Narasimhan, CEO of Novartis, to its Board of Directors. This appointment is significant because it brings deep expertise in highly regulated industries and the responsible deployment of breakthrough science to Anthropic's governance structure.

Governance Shift: Trust-Appointed Directors Now Hold Majority

With the appointment of Vas Narasimhan, directors appointed by the Long-Term Benefit Trust now constitute a majority of Anthropic's Board of Directors.

Anthropic operates as a Public Benefit Corporation. Its board is elected by a combination of stockholders and the Long-Term Benefit Trust. The Trust is an independent body composed of members with no financial stake in the company, designed to ensure that Anthropic's growth and financial success remain balanced with its public benefit mission of developing AI for the long-term benefit of humanity.

Vas Narasimhan's Expertise and Strategic Value

Vas Narasimhan is a physician-scientist and the CEO of Novartis, a leading innovative medicines company. His appointment is intended to provide the board with a critical perspective on scaling powerful technology safely within strictly regulated environments.

According to Daniela Amodei, Co-founder and President of Anthropic, Narasimhan has overseen the development and approval of more than 35 novel medicines, providing experience that aligns with Anthropic's goal of getting "powerful new technology to people safely and at scale."

Focus on AI in Healthcare and Life Sciences

Both Narasimhan and Anthropic share a conviction that healthcare and life sciences are primary areas where AI can most significantly improve human life. Narasimhan notes that AI is currently accelerating solutions for complex scientific challenges, including:

Deepening the understanding of disease biology.
Designing more effective medicines.

Professional Background of Vas Narasimhan

Vas Narasimhan's career spans global health and medical research, including early work on HIV/AIDS, malaria, and tuberculosis programs across India, Africa, and South America. His professional affiliations include:

Elected member of the US National Academy of Medicine.
Member of the Council on Foreign Relations.
Board of trustees for the University of Chicago.
Board of fellows at Harvard Medical School.
Former chair of the Pharmaceutical Research and Manufacturers of America.

Current Board Composition

Vas Narasimhan joins a Board of Directors that includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.